You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Asgard Therapeutics appoints chief medical officer

CS Analytical appoints director of Scientific Affairs

CrossBridge Bio to be acquired by Eli Lilly

IDEAYA Biosciences and Servier report positive results from Phase 2/3 trial of darovasertib/crizotinib combination

FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer

EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria

Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval

Lupin's Dapagliflozin Tablets launched in US market

Verastem Oncology presents two-year follow-up data on avutometinib and defactinib in recurrent low-grade serous ovarian cancer

DualityBio reports China NMPA acceptance of BLA for T-Pam for treatment of unresectable or metastatic HER2-positive breast cancer

DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules

Eli Lilly launches Foundayo weight‑loss pill in the US

AtaiBeckley reports rapid and durable Phase 2a responses to BPL‑003 in treatment‑resistant depression

Lupin's Dapagliflozin Tablets receive US regulatory approval

Dexcel Pharma's Nintedanib Capsules approved for US launch

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026